Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobimetinib + vemurafenib for BRAF V600-mutated cutaneous melanoma with brain metastases
2014-001671-30Phase 2Completed
- Sponsor
- Centre Eugène Marquis
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cobimetinib and vemurafenib in cutaneous melanoma (CM) and melanoma (3 cohorts), sponsored by Centre Eugène Marquis. Primary endpoint: Intracranial response rate in cohort A. Started Jul 2015; status: completed.
02
Drugs
cobimetinibvemurafenib
03
Conditions
cutaneous melanoma (CM)melanoma
Beyond the preview
Go deeper on 2014-001671-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001671-30.